Pharmacoeconomic evaluation of weight-based vs fixed-dose pembrolizumab for non-small cell lung cancer in China
Adopting a weight-based dosing strategy for pembrolizumab, especially when optimized with vial-sharing protocols, offers substantial and achievable annual cost savings for the Chinese healthcare system without compromising therapeutic efficacy. Therefore, this regimen should be considered as a potential first-line treatment option for patients with advanced NSCLC.
Authors
- Mei-Yu Wu (ORCID: https://orcid.org/0009-0005-4991-4422)
- Changcheng Shi (ORCID: https://orcid.org/0000-0002-8879-4794)
- Jianhua Ma (ORCID: https://orcid.org/0000-0001-9383-2559)
- Yuxi Yi (ORCID: https://orcid.org/0000-0002-6831-6920)
- Zixuan Zhang (ORCID: https://orcid.org/0009-0001-2461-0933)
- Chongqing Tan (ORCID: https://orcid.org/0000-0002-6007-4170)
- Andong Li (ORCID: https://orcid.org/0000-0001-5291-2720)
- Kehui Meng
- Xiaomin Wan
Institutions
- Central South University (CN)
- Second Xiangya Hospital of Central South University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-15
- DOI
- https://doi.org/10.3389/fimmu.2025.1665469
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Health Commission of Hunan Province
- National Natural Science Foundation of China
- Central South University
- Natural Science Foundation of Hunan Province